However, the experience and efficacy of anti-obesity drugs vary from person to person
One study found that exenatide, a GLP-1 agonist that was approved to treat Type 2 diabetes back in 2005, significantly reduced the alcohol-cue reactivity in the area of the brain related to drug reward and addiction and significantly reduced the total alcohol intake in patients with obesity in particular
For a full discussion of what happens during and after GLP-1 treatment, see our GLP-1 weight loss guide
Upon treatment with liraglutide, the effects of diabetic osteoporosis were reversed
Ray Kim 3 , 1 Perspectum Ltd, 2 Mayo Clinic Arizona, 3 Stanford University School of Medicine Background: The Steatosis-Associated Fibrosis Estimator (SAFE) score was developed to distinguish clinically significant (stage 2+) liver fibrosis among subjects with steatotic liver disease
Take the time to include all information and bring this up with your doctor so that they can select the most appropriate intervention given your medical status